전체메뉴 닫기

About

CEO
Message

Vision
& Mission

History

Corporate
Identity

Subsidiaries

Directions

Business

Overview

i-Cord Cord Blood Bank

Bio
Insurance

CHAUM

IT

CDMO

Overview of Matica BioLabs

Consulting

Genomics

R&D: Pipelines

Investors: Business Performance; IR
Presentations

ESG

ESG
Management

Environmental

Social

Governance

Articles of Incorporation

Board of Directors

Vision
& Mission

History

Corporate
Identity

About

History

2024

Selection of CBT101, an immune cell therapy for solid tumors, for government support under the National New Drug Development Program
Achievement of ISO27001:2022 certification for international information security standards
Joint development with CHA Vaccine Institute on a cancer therapy combining NK cells and immune boosters
Technology transfer agreement with U.S.-based CanCure for MIC-targeted antibody technology
Matica Biotechnology appoints CEO Paul Kim, a leading biotech and investment expert
Patent secured for the production method and material for highly activated NK cells
Launch of research on the anticancer efficacy of NK cell therapy using cationic polymers
CEO Sang Hoon Oh elected Chairman of the Korea Biopharmaceutical Association
CDMO contract signed with Cell in Cells for organoid-based therapies
Expanded collaboration with Centenaire Biosciences for combination studies involving NK cells and antibodies.

CHA Network

Company Name CHA Biotech Co., Ltd.
CEO Sang Hoon Oh

[Main Office] CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488

TEL: +82-31-881-7400
FAX: +82-31-881-7524

[Headquarter] PIE’N POLUS Building, 442 Dosan-daero, Gangnam-gu, Seoul

COPYRIGHT ⓒ 2024 by CHA Biotech, All rights reserved.

Affiliates

Global Healthcare

Related

Business